How Long Does Semaglutide and Tirzepatide Take to Work? The Trial Data on Onset, Appetite, and Weight Loss Timing

The most common patient question after starting a GLP-1 is some variant of “how long until this starts working?” The honest answer is that there are three different timescales the trial data measures separately, and understanding which one you're asking about determines the answer. Within hours of the first injection, gastric emptying slows and patients commonly report feeling fuller faster. Within 4-5 weeks at any given dose, the drug reaches steady state in plasma. Within 4-8 weeks, the scale starts moving meaningfully, and the full STEP-1 / SURMOUNT-1 weight-loss curves don't plateau until roughly week 60-68 [1, 2]. This article walks through all three timescales using the verified STEP-1 and SURMOUNT-1 trial data so you know what to expect at every milestone — and what to do if the curve doesn't match expectations.

Timescale 1: Appetite suppression (hours to days)

The fastest GLP-1 effect is the one patients feel first. GLP-1 receptor agonists slow gastric emptying — food stays in the stomach longer — and signal satiety in the hindbrain. Both effects begin within hours of the first injection, before the drug has even reached steady-state plasma levels [3, 5]. Patients typically report feeling fuller faster within the first 1-3 days of the first 0.25 mg semaglutide dose, with the effect strengthening as the dose escalates and as plasma concentration accumulates.

This early effect is real but it's also incomplete. The full appetite-suppression effect at each dose level is not reached until plasma concentrations approach steady state — which takes about 4-5 weeks per dose step (see Timescale 2 below). This is why the FDA-approved titration schedule keeps you at each dose for 4 weeks before increasing — the trial sponsors and the FDA both want you to feel the full effect of each dose before deciding whether to escalate [5, 6].

Timescale 2: Steady-state pharmacokinetics (4-5 weeks per dose)

The two FDA-approved injectable GLP-1s for weight loss have long elimination half-lives [3, 4]:

• Semaglutide (Wegovy, Ozempic): ~7 days elimination half-life [3]
• Tirzepatide (Zepbound, Mounjaro): ~5 days elimination half-life [4]

Steady-state plasma concentration is reached after 4-5 half-lives of constant dosing. For semaglutide that's approximately 4-5 weeks at any given dose; for tirzepatide it's approximately 3-4 weeks [3, 4]. This is the pharmacokinetic justification for the 4-week step interval in the standard FDA titration schedule. You can visualize this accumulation week-by-week with our GLP-1 dose plotter, which simulates the Bateman-equation buildup curves directly from the FDA prescribing information PK parameters.

Practically, this means: you should not expect a 0.25 mg semaglutide dose to feel like its full effect until somewhere in week 3-4 of taking it. If you feel almost nothing in the first week, that's normal and the curve has not finished rising yet.

Timescale 3: Measurable weight loss (weeks to months)

The third and slowest timescale is what most patients actually want to know about — when the scale moves. The STEP-1 and SURMOUNT-1 trials both measured body weight every few weeks across the full 68- and 72-week protocols, and the published data gives a clear week-by-week answer [1, 2].

STEP-1 (semaglutide 2.4 mg, n=1,961)

The STEP-1 trial (Wilding et al., NEJM 2021 [1]) reported the following mean body-weight reduction milestones for adults with overweight or obesity, no diabetes, on semaglutide 2.4 mg weekly with lifestyle intervention:

The trial-arm curve is not linear. The steepest weight loss happens between weeks 4 and 28 — once the patient is past the titration ramp and the maintenance dose is at steady state. After week 28, the curve flattens and continues to slowly decline through week 60-68 before plateauing.

SURMOUNT-1 (tirzepatide 15 mg, n=2,539)

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022 [2]) produced a similar but larger weight-loss curve over 72 weeks at the highest tirzepatide dose:

The shape is the same — fast in the first 6 months, slowing through year one, plateauing in the second half of the trial. Tirzepatide produces a larger total magnitude than semaglutide and reaches the larger plateau at roughly the same point on the calendar.

What to expect at each milestone

Combining the three timescales above, here's a practical week-by-week expectation guide for a patient starting semaglutide or tirzepatide on the standard FDA titration schedule:

If you're not seeing results — what the trial sub-analyses say

The STEP-1 and SURMOUNT-1 trial averages hide significant individual variation. About 86% of STEP-1 participants on semaglutide lost at least 5% of body weight, but that means roughly 14% lost less than 5% [1]. Similarly, ~91% of SURMOUNT-1 participants on tirzepatide 15 mg lost at least 5% [2], leaving ~9% who didn't. The reasons for non- response are not fully understood, but the standard clinical workflow when a patient is not losing weight after 12-16 weeks at the maintenance dose includes:

1. Confirm injection technique is correct (see our injection technique guide) — repeated injection into a lipohypertrophic site can reduce absorption by 25-50%.
2. Confirm the dose is being injected correctly — for compounded vials, the unit-vs-mg math is the most common source of error. Use our unit converter to check.
3. Confirm the dietary changes are present — GLP-1 therapy works alongside reduced caloric intake, not as a replacement for it. The trial protocols all included dietary counseling.
4. If all of the above are correct, discuss switching to tirzepatide (which produces larger weight loss in head-to-head comparison) or escalating to a higher dose if you're not yet at maintenance.

What to do during the slow phase

The trial curves above show that the rate of weight loss slows significantly after week 28. Many patients interpret this as “the medication stopped working” when in fact it's the natural shape of the curve and the same thing happened to ~90% of participants in the trials. The evidence-based actions during the slow phase:

• Stay on the maintenance dose; do not increase frequency or self-escalate above the FDA-approved maintenance.
• Add or strengthen resistance training to preserve lean mass during the slow-loss phase. See our semaglutide and muscle mass deep-dive for the trial-supported protein and resistance training targets.
• Track waist circumference and body composition rather than just total body weight — body composition often improves during the plateau phase even when the scale number is stable.
• Discuss long-term continuation with your prescriber. The STEP-4 trial showed that patients who stopped semaglutide at week 20 regained roughly 67% of the lost weight within one year, so discontinuation should be a deliberate decision rather than a reflex.

Related research and tools

For the visual buildup curves at each titration step, see our GLP-1 dose plotter. For the underlying side-effect profile that drives most early discontinuation, see our GLP-1 side effects investigation. For what happens after you stop, see our STEP-4 / STEP-1 extension review. For the full head-to-head comparison of semaglutide and tirzepatide, see our tirzepatide vs semaglutide head-to-head.